- Home
- NVS
NVS
Novartis AG
as of 03-30-2026 3:56pm EST
$150.43
+$2.14
+1.44%
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | 75267 | City: | N/A |
| Market Cap: | 278.6B | IPO Year: | N/A |
| Target Price: | $144.00 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $97.72 - $170.46 | Next Earning Date: | 04-28-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 2.56% | Revenue Growth (next year): | 4.91% |
| P/E Ratio: | 23.13 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | +8.26% |
AI-Powered NVS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 78.31%
78.31%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
Barrons.com
Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Fresh Economic Data
➖
AI Sentiment
Neutral
5/10
MT Newswires
Novartis Says Drug Improves Kidney Function in Patients With Berger's Disease
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline
📈
AI Sentiment
Highly Positive
9/10
Investing.com
Swiss-U.S. trade talks to blow past March deadline amid tariff uncertainty
➖
AI Sentiment
Neutral
4/10
GlobeNewswire
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
📈
AI Sentiment
Highly Positive
10/10
24/7 Wall St.
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
📉
AI Sentiment
Negative
3/10
Compare NVS vs Leading Stocks
See how NVS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.